A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined. Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program. Following major objective and subjective responses each patient underwent a surgical re-assessment and subsequently received single-agent intraperitoneal platinum (cisplatin or carboplatin). In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.